NCT06446193View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

February 6, 2025

Study Completion Date

February 6, 2025

Conditions
Autism Spectrum DisorderSocial Communication Disorder
Interventions
DEVICE

NDTx-01

NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.

BEHAVIORAL

TAU

TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education

Trial Locations (5)

42472

Daegu Catholic University Medical Center, Daegu

50612

Pusan National University Yangsan Hospital, Yangsan

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

All Listed Sponsors
lead

Neudive Inc.

INDUSTRY

NCT06446193 - To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD | Biotech Hunter | Biotech Hunter